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Abstract
Many potentially powerful therapeutic strategies for the treatment of disease require the delivery
of drugs into the cytosolic or nuclear compartments of cells. Members of the Irvine laboratory
have developed a novel pH-responsive core-shell nanoparticle system that can achieve efficient
and non-cytotoxic drug delivery into the cytosol. Another advantage is that the shell can be
easily modified to bind to different types of drug agents and incorporate ligands for specific cell
targeting. Experimental analysis of the newly synthesized nanoparticles with various shell
structures has demonstrated that modification of the shell does not compromise their cytosolic
delivery. These nanoparticles, if successful, will improve the therapeutic potential of a wide
range of drugs. However, critical issues on the research side need to be resolved, and an
appropriate intellectual property strategy should be initiated in the near future.
Applications to siRNA delivery and vaccines have been examined in depth, as cytosolic delivery
is one of the main challenges in these fields. Partnerships with large pharmaceutical companies
are critical in order to acquire key patents on siRNA/antigen. Even though the market is
competitive, there is a strong demand for innovative delivery platforms; provided that the overall
profile of the core-shell nanoparticles is comparable to that of emerging drug delivery systems,
and a strong intellectual property portfolio is developed, the Irvine technology should be able to
compete in the market.
After analyzing risks on the business side, including the FDA approval process, a suggested
business strategy is outlined, through which value can be successfully obtained throughout the
existing pharmaceutical supply chain from the novel drug delivery system. The Irvine
technology company will develop formulations, contract manufacturers will produce the
nanoparticles, and pharmaceutical companies will concentrate on clinical trials, late-stage
development and sales and marketing. A case study on the liver cancer market has demonstrated
that commercial development of the Irvine nanoparticles can be a financially successful endeavor.
Thesis Supervisor: Darrell J. Irvine
Title: Eugene Bell Career Development Associate Professor of Tissue Engineering
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1.0 Introduction
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Figure 1: Profitless growth of the biotechnology
industry 2.  being combinations of already approved products1 .
Most biotechnology companies have yet to make operating income (Figure 12). Some of the
recurring problems in drug development include low water solubility, instability, poor
pharmacokinetics and insufficient cell uptake of macromolecules, such as proteins. Many
scientists from diverse fields around the world have turned to advanced drug delivery system
technology, especially nanotechnology, to solve these challenges. Recent developments in the
Irvine laboratory have demonstrated that, through use of novel pH-responsive core-shell
nanoparticles, cytosolic delivery of drug molecules can be achieved. As many potentially
powerful therapeutics strategies for the treatment of disease, such as gene therapy mediated by
plasmid DNA, gene silencing or RNAi interference by oligonucleotides and therapeutic protein
delivery, depend on efficient cytosolic delivery, the technology has the potential to have a huge
impact on the healthcare industry.
2.0 Background
2.1 Cytosolic Delivery
Although small non-polar molecules can permeate through cell membranes, hydrophilic
macromolecules are internalized through three major types of endocytosis. Phagocytosis is an
active process performed by specialized cells via specific or non-specific receptors. Receptor-
mediated endocytosis is another active mechanism to uptake specific macromolecules and
involves clathrin-coated pits. On the other hand, macropinocytosis is a continuous, receptor-
independent and passive ingestion3 . These processes confine molecules in endosomes or
phagosomes where the pH is progressively decreased to 5.5-6.5. Upon fusion of these vesicles
with lysosomes, pH is further lowered to 4.5. The low pH environment and degradation
machinery of the vesicles often lead to rapid destruction of therapeutic agents without any
release into the cytosol (Figure 24). Therefore, cytosolic delivery presents a major challenge.
EXTRACELLULAR SPACE INTRACELLULAR SPACE
Delivery Drug
Materials Molecules
sSI)O0
7.4
Drug Delir••ry O
System
Figure 2: Typical pathway for intracellular drug delivery4.
2.2 Barriers to Cytosolic Delivery
In addition to the endolysosomal escape mentioned in section 2. 1, there are several
barriers to efficient delivery of drug molecules to the cell cytosol. First, a practical drug delivery
system should be able to detect the disease area and target specific cell types. This capability
would prevent widespread biodistribution of the drug delivery system after administration,
limiting immune responses and side effects from affecting normal tissues. Conjugation of
targeting moieties or antibodies specific to receptors expressed by target cells can not only
achieve specific cell targeting but also improve cellular uptake via receptor-mediated
endocytosis, which is another obstacle to cytosolic delivery5. Size and surface charge of the drug
delivery system are additional critical parameters for cellular uptake. Studies have shown that
positive surface charge is advantageous since the cell membrane possesses slightly negative
charge 6. After endolysosomal escape, drug molecules should be released from the drug delivery
system to the cytosol. Without unpacking of the drug cargos from their carriers, effective dosage
would be low. Although not essential as long as biocompatibility is met, biodegradability of the
drug delivery system to improve the safety profile is also of interest. For example, research on
polymeric carriers that can undergo hydrolysis or enzymatic degradation is ongoing7-9.
In summary, an ideal intracellular drug delivery system should be able to target specific
cell types, easily be taken up by cells, perform endolysosomal escape, release drug molecules
and undergo degradation to non-toxic components.
2.3 Past Approaches to Cytosolic Delivery and Their Limitations
As the importance of cytosolic delivery to increase therapeutic potential of drug agents
has been known for a long time, numerous approaches to the problem have been reported.
Physical methods, such as microinjection, exist, but they are highly invasive and cannot be used
for in vivo application. Therefore, most efforts have focused on developing drug delivery
systems that encapsulate or coat drug agents and deliver them to target cells. Although viral
vectors are highly efficient, immunogenicity and safety concerns are significant'0 . On the other
hand, liposomes are non-toxic, but not stable in vivo.
Polymeric carriers are promising because size, charge density and chemistry can be
tailored to achieve a desired functionality. In addition, polymers are stable and can be engineered
to have extended circulation time in the body11. One of the most widely studied polymer-based
delivery systems are based on hydrolytically degradable polyesters, such as poly(lactic-co-
glycolic acid) copolymers (PLGA). Although they are biodegradable and biocompatible, they
present several major limitations. First, hydrolysis of the ester backbone leads to an acidic
microenvironment that can denature drug molecules' 2. Furthermore, these materials cannot
perform endolysosomal escape. Most of the drug molecules are eventually degraded by low pH
and enzymes in endosomes before they can be released into the cytosol. Thus, these systems are
not suitable for intracellular drug delivery.
One of the earlier studies involved the use of polyethleneimine (PEI), polyhistidine and
polylysine systems that have the ability to escape endosomes through the "proton sponge" effect,
which will be described in section 2.4. However, significant cytotoxicity due to high cationic
density, which leads to perforation of cell membranes, is a major issue3-15. Also, strong
electrostatic binding between these polycationic materials and negatively charged therapeutic
agents prevents efficient release into the cytosol. Another approach has been directed at
developing synthetic chaperones that can facilitate transport of drug molecules across the cell
membrane. Examples include cell membrane penetrating peptides (CPPs) and pathogen-derived
pore-forming proteins 6. While many of these approaches show promise, a drug delivery system
that promotes efficient cytosolic delivery while avoiding cytotoxicity is still sought.
2.4 Nanoparticle Description
Members of the Irvine laboratory have developed novel crosslinked hydrogel
nanoparticles with core-shell structure that respond to the pH environment. As demonstrated in
Figure 317, the core of the nanoparticles is formed from polymerization of 2-diethylamino ethyl
methacrylate (DEAEMA) with poly(ethylene glycol) dimethacrylate (PEGDMA) as a crosslinker.
Because DEAEMA possesses a tertiary amine with a pKb of 7.0-7.3, the core is pH sensitive.
The amine groups become protonated during transition from the extracellular pH of 7.4 to the
endolysosomal pH of 5, which is responsible for a significant chloride accumulation in order to
maintain charge neutrality. The increase in osmotic pressure drives water uptake and swelling of
the particles, referred to as the "proton sponge" effect, and leads to disruption of the endosomes,
and release of the nanoparticles to the cytosol. The pH-insensitive outer shell is created from
polymerization of 2-aminoethyl methacrylate (AEMA). AEMA contains a primary amine group
that would normally be protonated. The outer shell is hydrophilic and therefore, mediates
drug/cell binding with low toxicity by shielding the hydrophobic core inside.
pH-sensitive core Crosslinker
H, HC 4H2 H2 CHý 45 3CHM
Diethylamino ethyl methacrylate Poly(ethylene glycol) dimethacylate
(DEAEMA) (PEGDMA)
pH-ln4 nsitive core Shel
extracellularlcylosolic pH endolysosomal pH H2c CH, 2C c
CH2  Ci 3
Methyl methacrylate (MMA) Aminoethyl methacrylate (AEMA)
Figure 3: Schematic structure and chemical composition of pH-responsive core-shell nanoparticles 7 .
2.5 Srnall Scale Production ofNanoparticles
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involves an oil-in-water (o/w) emulsion, is used to
produce the nanoparticles. Droplets of monomer are
emulsified in a continuous phase of water. Although
slightly hydrophobic, small amounts of monomer
diffuse through the water and undergo radical
polymerization in the presence of water-soluble
Figure 4: Theory of emulsion polymerization4.  lnators to orm growg parcles. s ese atex
particles are water-insoluble and possess similar
surface charge, they are prevented from coagulating with each other, leading to monodispersity
(Figure 44). The surfactant-free emulsion polymerization is a very simple synthetic process to
generate particles suitable for biological applications. In addition to control over size, surfactant-
free aspect allows the particles to be easily purified.
First, DEAEMA (lmL, 4.97mmol) premixed with PEGDMA 200 (10tL, 0.03mmol) are
dispersed in 9mL of water with stirring and equilibrated at 700C for 15 minutes before adding
ammonium peroxodisulfate (10mg) as the initiator. The emulsion polymerization is allowed to
proceed for 3 hours to grow the particle core, followed by injection of AEMA (40mg, 0.24mmol)
to grow the particle shell for an additional 1.5 hours. The nanoparticles are purified by dialysis in
deionized water for 3 days, followed by ultrafilitration and centrifugation at 15,000rpm. The
nanoparticles are stored in phosphate buffered saline (PBS) solution at 40C until needed 7 .
2.6 Distinguishing the Irvine Nanoparticles
The Irvine nanoparticles are highly monodisperse, with the size being approximately
200nm at pH of 7.4 and temperature of 370C. The swelling transition occurs at a narrow range of
pH (6.8 to 7.0 at 370C), and the diameter and volume changes between pH 5 and 7.4 are 2.8 and
22 fold, respectively (Figure 517). The Irvine group has demonstrated that the nanoparticles are
stable, efficiently deliver ovalbumin as model drug molecules to the cytosol and have low
cytotoxicity. The proposed mechanism of cytosolic delivery is confirmed through multiple
experimental data.
Irvine nanoparticles offer many advantages over existing technologies for the cytosolic
delivery. Synergy of these properties is responsible for novelty of the research.
* Efficient cytosolic delivery of membrane-impermeable molecules
* Low cytotoxicity through the core-shell structure
* Control over the particles size, chemical groups and stability
o Optimal size for cellular uptake
o Monodispersity
o Ease of targeting ligand introduction
o Ability to load many types of drug agents with the outer shell modification
* Inexpensive process
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2.7 Hype over Nanoparticle Drug Delivery Systems
Since the early to late 1990s, nanoparticle technology has seen an explosion in terms of
research in the pharmaceutical industry. Many scientists believe that nanotechnology offers an
excellent opportunity to address the challenging needs and requirements of the newer drug
moieties in order for them to exhibit their targeted therapeutic effect. This has led to introduction
of new terms, such as nanomedicine and nanobiotechnology. More than 1,650 articles related to
nanotechnology and drug delivery since 2005 indicate the extent of interest in this field.
Government funding dedicated to nanotechnology is abundant. The National Science Foundation
has predicted that by 2010, nanotechnology based-drug delivery applications will account for
half of all the pharmaceutical sales. Industry analysts predict that annual drug revenue in the
nano-pharma market will grow by $80 to 200 billion by the year 2015 to 20201.
Figure 5: Mi
However, many of the current nano drug delivery systems, including the Irvine
nanoparticles, are remnants of conventional drug delivery systems that happen to be in the
nanometer range18 . In fact, nanoparticles were first developed approximately 35 years ago' 9
Despite the hype created by the industry and market, formidable challenges do remain. Therefore,
it is important for one to critically analyze all the risks involved in transferring the technology
from laboratory to market. Through an iterative process, one can assess whether the Irvine
technology will be able to be commercialized and generate a profitable business model. Some of
the risks are listed in Table 1 and will be discussed throughout the thesis. Adaptability due to
broad research and broad applications can mitigate these risks.
Research Side Commercialization & Market Side
Loading of the actual drug molecules Human clinical trials
Incorporating biodegradability Long time horizon
Specific cell targeting Manufacturing process
Route of administration Overestimation of the market
Table 1: Risks involved in commercializing the Irvine nanoparticles.
3.0 Nanoparticles with Different Shell Structures (Research)
3.1 Purpose of the Study
One of the advantages of the Irvine nanoparticles is that emulsion polymerization allows
composition of the shell to be separately tuned to facilitate particle targeting, cell binding, and
drug binding. To analyze whether modifications of the shell structure compromise the
endosome-disrupting function of the pH-responsive core, various analogs of the core-shell
particles were synthesized. This section summarizes the design of these nanoparticles and
discusses their pH-responsivity, surface charge and cytosolic delivery assay results.
3.2 Materials and Methods
3.2.1 Materials
All reagents were used as received without further purification. 2-aminoethyl
methacrylate hydrochloride (AEMA, 90%), methacrylic acid (MAA, 99%), calcein and
ammonium peroxodisulfate (APS) were purchased from Sigma-Aldrich Chemical Co.
Poly(ethylene glycol) dimethacrylate (PEGDMA, MWPEo = 200g/mol) and poly(ethylene glycol)
monomethyl ether monomethacrylate (PEGMA, MWPEO = 1,000g/mol) were acquired from
Polysciences Inc. Cy3 mono-NHS ester was from GE Healthcare UK Limited. RPMI 1640,
DMEM (with 4.5g/L glucose) and Trypsin EDTA (0.25% trypsin/2.2lmM EDTA in HBSS
without sodium bicarbonate, calcium and magnesium) were purchased from Mediatech Inc., and
fetal bovine serum (FBS) was purchased from Hyclone.
3.2.2 Methods
3.2.2.1 Synthesis of the Core-Shell Nanoparticles
The procedure outlined in section 2.3 was followed to form the particle core. In order to
assess whether variation of AEMA concentration and addition of PEGDMA crosslinker during
the shell growth had an impact on the structure of the nanoparticles, pH-responsivity and
endosome-escaping capability, four samples were prepared (Table 2). Monomer concentrations
in AEMA_H and AEMAH_X samples were higher than those of AEMA_L and AEMA_LX
samples by a factor of 10. For AEMAL_X and AEMA_H_X samples, the molar ratio of the
crosslinker to the monomer was maintained at 0.03 to 4.97, identical to that during the core
growth. Total weights of the shell reagents in AEMA_L_X and AEMA_H_X samples were kept
at 40mg and 400mg, respectively.
Mnaimer PEGDMA Water
AEMAL
AEMA L X
AEMAAH
AEMA HX
40mg (0.24mmol) None 50L
39.5mg (0.24mmoi) 0.5pL (l. 44 pmol) 50i.L
400mg (2.40mmol) None 300juL
394,9mg (2.38mmol) 4.8pL (14.39=pmol) 300pL
Table 2: Samples prepared with different AEMA concentrations with or without PEGDMA crosslinkers. L: low
concentration of AEMA; H: high concentration of AEMA; X: addition of PEGDMA crosslinker.
To synthesize the core-shell particles with different shell monomers and surface charges,
six samples were prepared as listed in Table 3. Weights of the shell monomer in AEMA,
PEGMA and MAA samples were 200mg, and the molar ratio of the crosslinker to the monomer
was maintained at 0.03 to 4.97. Total weights of the shell reagents excluding the crosslinker in
AEMA_P, PEGMAP and MAA_P samples were 40mg. The ratio of the shell monomer to
PEGMA in AEMA_P and MAA_P samples was 1 to 2 by weight.
Monomer PEGMA PEODMA Water
AEMA
AEMA P
PEGMAP
MAA
MAA P
200mg (21.20nmo) None 2.4pL (7.24npmol) lO1pL
13.3mg (O.0Sunmmo) 24.2pL (0.02mmol) 0.5pL (1.52jmml) 50piL
200mg (0.1 Smmol) NIA Q.4pL (1. Il mol) 100pL
40mg (0.04mmol) N/A 0.5pL (,52pnml) 50ipL
0.197mL (2.32mmo) None 4.6pL (14.02Imol) 100jiL
13.IpL (O.15mmol) 24.2pL (0.02mmol) 0I5pL (1.52pmol) 50pL
Table 3: Samples prepared with different shell monomer with or without PEGMA. P: addition of PEGMA.
After 3 hours of core synthesis, above reagents were injected to grow the particle shells
for an additional 1.5 hours. The nanoparticles were purified by dialysis (3,500 MWCO Slide-A-
Lyzer" Dialysis Cassettes, Pierce Chemical Co.) in deionized water for 3 days, followed by
centrifugation (3X, lmL PBS buffer (pH 7.4), at 15,000rpm for 15 minutes each). Purified
particles were stored in PBS buffer at 40C until needed.
3.2.2.2 Characterization of the Core-Shell Nanoparticles
To characterize the pH sensitivity of the newly synthesized core-shell nanoparticles, the
hydrodynamic diameters, determined by dynamic light scattering (DLS, Brookhaven 90Plus
instrument, 6 runs with 30 seconds of duration), were measured for particles equilibrated in
100mM phosphate buffers of different pHs at 250C. Surface charges of the nanoparticles were
analyzed from zeta potential measurements (Brookhaven ZetaPALS instrument, Smoluchowski
model, 10 cycles with 15 seconds of duration). The purified particles were equilibrated in 5mM
sodium chloride solution at 250 C, and pH was adjusted using 0.1M sodium hydroxide and 0.1M
hydrogen chloride solutions. Finally, concentrations of the particles were measured by their dry
weight following lyophilization. After centrifuging 0.5mL of each sample at 15,000rpm for 5
minutes, the particles were flash-frozen in liquid nitrogen and lyophilized over 2 days.
3.2.2.3 Cell Culture
DC2.4 cells, a dendritic cell clone originally derived by Shen et al.20 , were a gift from
Professor Kenneth Rock. These cells were cultured and passaged in complete RPMI 1640
medium containing 10% FBS, 50ýtM 2-mercaptoethanol, 5mM L-glutamine, 10mM HEPES, and
penicillin/streptomycin.
3.2.2.4 Cytosolic Delivery of Calcein
The particles were fluorescently labeled by incubating Cy3 mono-NHS ester (5[tL of
lmg/mL solution in DMSO) with 100[tL of each sample in 395[tL of PBS buffer overnight at
4oC. Unconjugated dye was removed by centrifugation (3X 0.5mL PBS buffer, at 15,000rpm for
15 minutes each). The labeled particles were resuspended and stored in PBS buffer at 40C.
Calcein, a membrane-impermeant fluorophore, was used as a model drug molecule and
tracer to monitor the stability of endosomes/phagosomes following particle uptake21. DC2.4 cells
were plated in Lab-TekTM chambers (Nunc 8-well chambered coverglasses, 1.2 x 105 cells/well),
and then calcein was added to the cells (150[tg/mL, 0.24mM) with or without 25[tg/mL of
different core-shell nanoparticles in complete medium for 1 hour at 370 C. After three washes
with medium to remove extracellular calcein/particles, the cells were imaged live by Zeiss LSM
510 Confocal Laser Scanning Microscopy (CLSM) at 370 C.
3.3 Results and Discussion
3.3.1 Variation of AEMA Concentration and Addition of PEGDMA Crosslinker
3.3.1.1 Characterization of the Core-Shell Nanoparticles
Variation of AEMA concentration and addition of PEGDMA crosslinker during the shell
growth were expected to influence the surface structure of the nanoparticles. Increasing
concentration of AEMA on a scale comparable to that of DEAEMA would induce faster growth
of the shell, enlarging the particles. On the other hand, introduction of PEGDMA would cause
the shell to undertake hydrogel structure instead of a brushy layer. Without additional PEGDMA,
AEMA monomers or linear chains of AEMA would crosslink to unconjugated ends of
PEGDMA of the core.
However, as shown in Figure 6, modification of the shell did not impact the pH-
responsivity and monodispersity of the core-shell nanoparticles. Similar to the original
nanoparticles, they were largely deswollen at elevated pH but swelled abruptly between pH 7.4
and 7.0 at 250C. With pKb of approximately 11, the primary amines of the AEMA groups in the
particles shells should remain highly ionized across the relevant pH range. Only the tertiary
amines of the particle cores, which possess pKb of 7.0-7.3, respond to the changes in pH. The
swelling transition of AEMA_H and AEMA_H_X nanoparticles occurred at slightly higher pH
compared to AEMA_L and AEMA_L_X nanoparticles. Since the swelling response of
DEAEMA-containing nanoparticles have shown to be sensitive to temperature, the swelling
transition of these particles is expected to shift to lower pH at physiological temperature (370C)17.
From the DLS data, it is difficult to conclude that higher AEMA concentration increased
the hydrodynamic diameters of the nanoparticles. Although AEMA_H particles were bigger than
AEMAL particles, AEMA_H_X particles were slightly smaller than AEMA_ L X particles.
First, the reaction conditions for different samples were not identical. With use of a multi-stir
plate, stir rate could have been different, influencing size of the core and the shell. Temperature
of the reaction solution could have been not uniform and varied from sample to sample. This led
to formation of a membrane at the top, making injection and dissolution of the shell reagents
difficult. In addition, size of the core particles before the shell growth was not measured. It is
possible that the difference in the particles size could have resulted from the core, not the shell.
One should also note that all the nanoparticles, including the positive control (AEMA_L), were
larger than expected. The original particles exhibited the diameters of 208-4nm at 370C in PBS
buffer1 . Since particle size is a critical parameter for cellular uptake, it is important to have
reproducible experimental control over particle size. Nevertheless, the particles displayed a
similar change in diameter and volume on moving from the extracellular/cytosolic pH of 7.4 to
an endolysosomal pH of 5 compared to the original ones.
Diameter vs. pH
Figure 6: pH-responsivity of the core-shell nanoparticles synthesized from low or high concentration of AEMA
with or without PEGDMA crosslinkers during the shell growth. (*) AEMA_L; (o) AEMAL X; (A) AEMA_H;
() AEMAHL.
Zeta potential measurements of AEMA_H and AEMA_H_X nanoparticles were expected
to be higher than those of AEMA_L and AEMA_L_X nanoparticles. With higher concentration
of AEMA to increase their incorporation on the shell, surface charge would be more positive.
According to Table 4, such conclusion cannot be made. Around pH 9, values for AEMA_H and
AEMA_H_X particles were bigger than those of AEMAL and AEMA L X. However,
observation was the opposite at pH of 7.4. Determination of the shell structure is needed in order
to explain the data. Finally, concentrations of these nanoparticles after purification and
lyophilization were between 0.02g/mL and 0.04g/mL.
Sample Zeta Potential (pH 7.4) Zeta Potential (pH 9)
AEMAL 37.10±2.55mV 3.18±0.82mV
AEMA L X 36.23±1.26mV 8.59+1.14mV
AEMA H 36.05±1.77mV 14.59±0.84mV
AEMA H X 29.41±0.92mV 16.54±1.99mV
Table 4: Zeta potential measurements of the core-shell nanoparticles synthesized from low or high concentration of
AEMA with or without PEGDMA crosslinkers during the shell growth.
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3.3.1.2 Cytosolic Delivery of Calcein
It was hypothesized that the pH sensitivity of the newly synthesized core-shell
nanoparticles would facilitate endosome/phagosome disruption through the "proton sponge"
effect and swelling of the particles. Because of the interest in delivering membrane-impermeable
molecules into dendritic cells for vaccines and antiviral drug delivery, the uptake of the
nanoparticles by a dendritic cell clone DC2.4 was investigated. As shown in Figure 7A,F, cells
treated with calcein alone showed a punctuate distribution of fluorescence indicative of
endolysosomal compartmentalization of the dye. In contrast, cells co-incubated with calcein and
the core-shell nanoparticles exhibited calcein fluorescence throughout the cytosol and nucleus
(Figure 7B-E and Figure 7G-J). The confocal images show that the particles were taken up by
the phagocytic DC2.4 cells, leading to the phenomenon. The nanoparticles deliver calcein to the
cytosol of cells by co-endocytosis of calcein and particles, followed by particle disruption of
endosomes and escape of the dye into the cytosol/nucleus (note that calcein that reaches the
cytosol is also able to freely enter the nucleus by diffusion). Since the pH-responsive core is
responsible for the cytosolic delivery of the particles, it was expected that modification of the
shell structure would have minimal impact.
r igure /: pti-responsive core-snell nanoparticles chaperone the delivery of the membrane-impermeable dye
molecule calcein into the cytosol of dendritic cells. (A-J) CLSM images at 40x. (A-E) Bright-field images. (F-J)
Fluorescence overlays (red, nanoparticles; green, calcein). (A,F) Cells were treated with calcein alone. (B,G) Cells
were co-incubated with calcein and AEMA_L nanoparticles. (C,H) Cells were co-incubated with calcein and
AEMA_L_X nanoparticles. (D,I) Cells were co-incubated with calcein and AEMA_H nanoparticles. (E,J) Cells
were co-incubated with calcein and AEMA_H_X nanoparticles. Scale bar: 20tm.
3.3.2 Variation of the Shell Monomer and Surface Charge
3.3.2.1 Characterization of the Core-Shell Nanoparticles
O O
SNH2 OH
AEMA PEGMA MAA
Figure 8: Shell monomers used to form different core-shell nanoparticles.
Nanoparticles with various shell structures that can bind to different types of drug
molecules were synthesized. AEMA particles can associate with negatively charged molecules
whereas PEGMA and MAA particles can complex with non-ionic polar and positively charged
molecules, respectively (Figure 8). PEGMA monomers have been introduced to AEMA_P and
MAAP samples in order to prevent aggregation of the particles. In addition to improving
stability of the particles, the poly(ethylene glycol) (PEG) moieties in PEGMA can also improve
drug delivery properties by inhibiting protein binding that has been known to lead to
opsonization and phagocytosis. Numerous studies of coupling PEG chains to decrease immune
system recognition and subsequent clearance have been reported22.
As shown in Figure 9, modification of the shell structure and surface charge did not
influence the pH-responsivity and monodispersity of the core-shell nanoparticles. Similar to the
original nanoparticles, they were largely deswollen at elevated pH but swelled abruptly between
pH 7.4 and 7.0 at 250C. The swelling transition of the particles should occur at lower pH at 370C.
With incorporation of PEGDMA crosslinkers, these nanoparticles possessed hydrogel
structure in the shell. AEMA and PEGMA particles, synthesized from 200mg of monomers,
exhibited similar hydrodynamic diameters. DLS data for MAA particles are not shown in Figure
9, as they could not be completely purified; centrifugation did not yield solid pellets. In addition,
MAA particle solution was viscous and slightly transparent after dialysis, unlike milky solutions
of AEMA and PEGMA particles. However, it is expected that MAA sample would display
similar particle size, monodispersity and pH responsivity. Total weights of the shell reagents
excluding the crosslinker were 40mg for AEMA_P, PEGMA_P and MAA_P samples. Therefore,
the hydrodynamic diameters of AEMA_P and PEGMA_P particles were less than those of
AEMA and PEGMA particles, respectively. However, effects of shell monomer variation and
PEGMA addition on the particle size cannot be determined from the DLS data for the reasons
stated in section 3.3.1.1.
Figure 9: pH-responsivity of the core-shell nanoparticles synthesized from different shell monomers and PEGDMA
crosslinkers with or without PEGMA during the shell growth. (.) AEMA; (o) AEMA_P; (A) PEGMA; ( )
PEGMA_P; (m) MAA_P.
Zeta potential measurements for the newly synthesized nanoparticles are shown in Figure
10. At physiological conditions, values for the particles synthesized from AEMA were expected
to be positive whereas values for the particles synthesized from MAA were expected to be
negative (note that AEMA and MAA possess pKb and pKa of approximately 11 and 5,
respectively). On the other hand, with non-ionic shell monomers, PEGMA and PEGMAP
particles were anticipated to display near-neutral zeta potential values. In addition, thicker shells
of AEMA and MAA particles were expected to increase the magnitude of the values compared
to AEMA_P and MAA_P particles. However, all the nanoparticles possessed positive values at
low pH and negative values at high pH. In general, the isoelectric point was around pH 9. The
values were very similar for AEMA, PEGMA and MAA particles, and the isoelectric point of
PEGMA particles was lower than that of AEMA and MAA particles. The values for AEMA_P,
PEGMA_P and MAA_P particles were bigger at low pH.
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One possible source of error was impurity of MAA particles, as previously mentioned.
Also, 3,500 MWCO cassettes instead of 10,000 MWCO cassettes were used for purification.
This could have made dialysis less efficient, and side products and unused reactants could have
remained in the particle solutions. Lack of data points could have prevented accurate
interpretation of the results. Another possibility was that the zeta potential machine was reading
the surface charge of the core, which was much thicker than the shell. The group of Armes has
shown that DEAEMA-containing latex particles exhibit the isoelectric point around pH 9, similar
to that of the newly synthesized core-shell particles 23' 24. In addition, the shell could have been
formed from both the shell monomer and DEAEMA, which was evidenced by Nuclear Magnetic
Resonance (NMR) analysis. The molar ratio of the shell monomer to DEAEMA after the second
stage of synthesis was 1 to 2 (data not shown). Presence of DEAEMA on the shell could explain
why all the particles displayed positive zeta potential values at physiological conditions.
Nigure 10: Leta potential measurements of the core-shell nanoparticles synthesized from different shell monomers
and PEGDMA crosslinkers with or without PEGMA during the shell growth. (*) AEMA; (o) AEMA_P; (A)
PEGMA; ( :) PEGMA_P; (m) MAA; (i) MAA_P.
3.3.2.2 Cytosolic Delivery of Calcein
Similar to the results from section 3.3.1, cells co-incubated with calcein and the core-
shell nanoparticles exhibited fluorescence throughout the cytosol and nucleus (Figure 11B-D and
Figure 11 F-H). As displayed by the confocal images, the particles were internalized by the
phagocytic DC2.4 cells. The nanoparticles deliver calcein to the cytosol of cells by co-
endocytosis of calcein and particles, followed by particle disruption of endosomes and escape of
the dye into the cytosol/nucleus. Since the pH-responsive core is responsible for the cytosolic
delivery of the particles, it was expected that variation of the shell monomer and surface charge
would have minimal impact.
Figure 11: pH-responsive core-shell nanoparticles chaperone the delivery of the membrane-impermeable dye
molecule calcein into the cytosol of dendritic cells. (A-H) CLSM images at 40x. (A-D) Bright-field images. (E-H)
Fluorescence overlays (red, nanoparticles; green, calcein). (A,E) Cells were treated with calcein alone. (B,F) Cells
were co-incubated with calcein and AEMA nanoparticles. (C,G) Cells were co-incubated with calcein and PEGMA
nanoparticles. (D,H) Cells were co-incubated with calcein and MAA nanoparticles. Scale bar: 20Rm.
3.4 Conclusions
Different types of pH-sensitive core-shell nanoparticles have been synthesized and
analyzed. Variation of the surface structure by increasing the monomer concentration, adding
PEGDMA crosslinker and changing the monomer during the shell growth did not influence the
pH-sensitivity and cytosolic delivery of membrane-impermeable calcein to dendritic cells. The
results demonstrate flexibility and broad applicability of the nanoparticles, as they can bind and
deliver different types of drug agents. However, further research needs to be conducted to
directly determine the shell structure. Ovalbumin binding assay to differentiate the nanoparticles
is under investigation. Since the protein is negatively-charged, the particles synthesized from
AEMA are expected to bind to ovalbumin more effectively than the particles synthesized from
PEGMA and MAA. It might also be necessary to find a strategy to prevent incorporation of
DEAEMA on the shell to decrease cytotoxicity and to improve binding efficiency between the
core-shell particles and drug molecules.
4.0 Additional Improvements to the Irvine Nanoparticles
Although the fundamental issue of cytosolic delivery has been solved, critical short-term
barriers on the research side, including the ones discussed in section 3, must be overcome for the
technology to be viable for commercialization. First, loading of the actual drug molecules needs
to be performed. As shown in Figure 12, electrostatic interaction between oppositely charged
drug agents and the shells of the nanoparticles has been proposed4 . One concern is that binding
competition with endogenous proteins could decrease the bound drug molecules on the
nanoparticles before endocytosis. In addition, ribonucleases and proteases could access the drug
molecules on the shells and degrade them. Encapsulation of the therapeutic agents in the shell, in
the core, or between the shell and the core could be a potential method for drug loading and
protection. This could reduce the drug dosage and avoid frequency of drug treatments.
Drug Molecules Core-Shell Nanoparticles
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Figure 12: Electrostatic interaction between the core-shell particles and the drug molecules4 .
As implied above, sufficient electrostatic interaction between the drug molecules and the
nanoparticles is necessary to withstand binding competition with other proteins in the body.
However, overly strong electrostatic force could inhibit efficient unpacking of the drug agents.
Initial mRNA knockdown experiments demonstrated that the Irvine nanoparticles achieve less
Y I
siRNA delivery than commercially available lipid transfection agents under certain conditions
(Figure 134). Strong electrostatic interaction might inhibit siRNA release from the shells once in
the cytosol. Incorporating digestible crosslinkers to the hydrogel, such as bis(acryloyl) cystamine
(BAC) that can be degraded in the presence of intracellular level of glutathione, is a possible
solution. This approach not only has the potential to increase intracellular release of siRNA, but
also improve the safety profile of the nanoparticles. Lack of biodegradability with the current
drug delivery system could be of great concern since biodistribution of the nanoparticles in the
bloodstream and accumulation in the kidney and spleen might induce immune response and
long-term toxicity25. Since DEAEMA homopolymer breakdown products could be toxic to cells,
incorporation of hydrophilic PEG methacrylate in the core is being investigated 26. After cleavage
of the BAC crosslinks, the PEG chains would extend into solution, forming a unimolecular
micelle and hiding hydrophobic DEAEMA backbone units. It is hypothesized that such a
micellar breakdown product could be safely eliminated from cells and eliminated from the body.
Figure 13: Knockdown of intracellular mRNA level by different drug delivery systems4.
Another important issue to be addressed in the near future is determining the route of
administration. It would depend on specific application, but intravenous delivery is most
plausible. Although more invasive than other methods, it offers several advantages. First, the
nanoparticles, when thus administered, can potentially reach disease that is either disseminated,
making local injection difficult, or too small to be detected27 . Oral delivery is not feasible since
degradation machinery of the stomach and the gastrointestinal tract can destroy the nanoparticles.
In addition, the acidic pH environment will enlarge the nanoparticles, making their absorption
even more challenging. Parental and nasal passages are other possibilities, but bioavailability can
be significantly limited. Another attractive feature of systemic administration is that enhanced
permeability and retention (EPR) effect can be fully utilized for passive targeting of tumor cells.
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As tumors grow and begin to outstrip the available supply of oxygen and nutrients, they release
cytokines and other signaling molecules that recruit new blood vessels, in a process called
angiogenesis. Angiogenic blood vessels have gaps as large as 600 to 800nm between adjacent
endothelial cells, and the nanoparticles can easily extravasate into the tumor interstitial space28
As mentioned in section 2.6, size of the nanoparticles is around 200nm at physiological
conditions. The particles are expected to display relatively long half-life. This is because the
kidney removes particles smaller than 2 to 3nm whereas the reticuloendothelial system (RES)
physically captures less than 70nm particles in its tissues and clears those greater than 200nm in
diameter. One potential drawback is that these particles would have difficulty infiltrating target
tissues since only small particles of 1 to 3nm in size can escape vasculature, except for the leaky
blood vessels of tumors. A possible solution is to slightly reduce the size of the particles and
sacrifice their half-life, provided that it would have minimal impact on their cellular uptake and
endosome-disrupting function. This can also increase their biocompatibility, as smaller particles
can be excreted more easily.
Furthermore, conjugation of ligands to the shell should be investigated to target specific
cell types and prevent widespread biodistribution of the nanoparticles. Finally, in vivo data is
required before clinical trials can be conducted. Critical issues like the ones described in this
section indicate that the technology is still at the university research stage. As described in Figure
14, technological barriers of complexity that might be greater than the fundamental issue of
cytosolic delivery do remain. Resolving them in the near future will not only reduce the degree
of risk on the research side but also improve patentability of the technology.
Critical research issues
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Figure 14: Technological barriers of commercializing the core-shell nanoparticles.
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5.0 Initial Patent Analysis
5.2 Patentability of the Irvine Nanoparticles
If one is to pursue commercialization of this technology, the components and the process
of producing the nanoparticles have to be patented regardless of the market sectors and business
strategies. Otherwise, there are no means of protecting the technology due to simple
experimental protocol and publication of the relevant data in 2007. In order to assess
patentability, there must be no prior art information. A patent search was performed with regards
to different aspects of the technology.
5.2.1 Patents Related to pH-Responsive Polymers
Although several intellectual property rights on pH-responsive polymers exist, none of
the systems use DEAEMA. Professor Robert Langer at Massachusetts Institute of Technology
holds a number of patents in this area. U.S. Patent No. 6,998,115 claims biodegradable and
biocompatible nanoparticles formed from various poly(3-amino esters) that become hydrophilic
and soluble at acidic pH. They can be used to deliver surface-complexed polynucleotides or
encapsulated drugs29. However, chemical structures of the nanoparticles are significantly
different. In addition, Professor Langer's U.S. Patent No. 6,692,911 covers biodegradable and
biocompatible drug delivery systems that utilize the "proton sponge" mechanism. As the patent
claims systems comprising of polyhistidine and polylysine, it does not appear to cover the
compositions used in the Irvine nanoparticles30.
5.2.2 Patents Related to Synthesis of the Irvine Nanoparticles
Because emulsion polymerization has existed for a long time, there should not be any
patents preventing the process of synthesizing the Irvine nanoparticles. For completeness, a
patent search was conducted. One patent, assigned to Rohm and Haas, deserves particular
attention. It claims a process for continuous production of crosslinked polymeric nanoparticles of
1 to 100nm in diameter. Although the size of the current Irvine nanoparticles is not within the
proposed range, it may limit the extent of the technology. However, the patent is not yet issued,
and the broad claims may become limited 31
5.2.3 Additional Relevant Patents
One of the patents that appear to be most troublesome for the Irvine nanoparticles is
assigned to Instituto Superiore Di Santa in Italy. It describes core-shell nanoparticles for delivery
of proteins and nucleotides obtained through emulsion polymerization, where the core is formed
from water-insoluble polymers, and the shell is formed from hydrophilic polymers. The
description of the components and proposed applications is very similar to those of the Irvine
nanoparticles. It claims DEAEMA as a possible monomer for the core and also covers
nanoparticles that comprise of at least one pharmacologically active agent adsorbed on the
surface. Fortunately, the nanoparticles claimed possess corona structure without any use of
crosslinkers instead of the hydrogel structure. In addition, the patent does not claim AEMA for
the shell monomer 32. U.S. Patent No. 7,129,293, assigned to Japan Science and Technology
Agency, is another intellectual property that describes core-shell nanoparticles formed from
DEAEMA. However, it claims copolymer structure with addition of polyethylene glycol
segment and covers completely different core-shell structures 33. To ensure that improvements to
the current technology, described in the previous section, are patentable, further search was
conducted. Even though one patent claims reversible hydrogel system that contains disulfide
crosslinkers, including BAC, it is synthesized from different monomers 34
5.2.4 Literature Search
Because publicly disclosed data can also obstruct a patent from being issued, literature
search was also performed. There is a possibility that an author has recently made his/her data
public, but has not yet filed a patent. Focus was on the pH-responsive drug delivery systems that
consist of DEAEMA, published in primary literature. DEAEMA hydrogels for drug delivery
purposes do exist, but their mechanisms of action and chemical structures are significantly
different from the Irvine nanoparticles3 5' 36
5.2.5 Preliminary Intellectual Property Strategy
From the in-depth patent and literature search, the Irvine nanoparticles and their
improvements should be patentable, including the ones with different shell structures and
biodegradable crosslinkers. However, it is important to keep in mind that a patent gives the right
to prohibit somebody from using a technology, but does not automatically endow freedom to
operate. Therefore, additional patent search is required to address intellectual property issues
with complexing the Irvine nanoparticles with specific drug agents, such as siRNAs and protein
antigens. This will be covered section 5.
A preliminary intellectual property strategy is proposed, and the course of action depends
on whether the critical issues on the research side are resolved or not in the near future. First of
all, with the current technology, there is no eligibility in foreign countries as the data were
published in September of 2007. In the U.S., there is a one-year grace period, and a provisional
patent, which can be as cheap as $105, on the publicly disclosed information should be filed as
soon as possible. There are two scenarios.
Scenario A: If the critical issues, such as drug loading/unloading and biodegradability,
are resolved a few months before September of 2008, an additional provisional patent should be
filed on the same day of public disclosure of the new improvements to obtain foreign rights. This
is an important issue since Europe and Japan are significant markets, as will be discussed later.
Then, sources of funding other than venture capital, such as angel investors, Small Business
Innovative Research (SBIR) and other government funding, should be identified before filing
non-provisional patents. Although the cost of obtaining a patent can vary greatly depending on
its complexity, these investments should be sufficient to cover the necessary fee and to form a
start-up company.
Scenario B: If the critical issues are not overcome before September of 2008, one should
forfeit the original priority date and file another provisional application, if allowed, to obtain
another year. If this is not possible, the provisional patent should be forfeited and wait for the
problems to be solved. If they cannot be solved after significant time investment, one should
reconsider commercializing the technology.
6.0 Potential Applications
6.1 Overview
Because many therapeutic strategies for the treatment of disease depend on efficient
delivery of drugs into the cytosolic or nuclear compartments of cells, the number of applications
for the technology is virtually unbounded. By modifying the shell structure, numerous types of
therapeutic agents can be loaded on the nanoparticles. The thesis will focus on two applications:
siRNA delivery and vaccines. As will be discussed, cytosolic delivery is one of the main
challenges in these fields, and overcoming the barrier can lead to treatment of deadly diseases,
including cancer, HIV, malaria and hepatitis C virus. Delivering DNA for treating chronic
diseases and genetic disorders is another possibility, but it requires an additional mechanism for
nuclear uptake. In addition, despite years of research, safety concerns due to genetic disruption
still reside. Since 1990, scientists have led more than 1,300 gene therapy trials worldwide, but
only one, in China, has so far yielded a marketable product 37. For small molecules, which can
easily permeate through cell membranes, other tactics of delivery improvement can easily be
employed.
6.2 siRNA Market Analysis
6.2.1 Introduction to siRNA
Since the completion of the Human Genome Project, nucleic acid-based approaches for
gene silencing in a sequence-specific manner have become powerful tools. There are three main
technologies to silence genes responsible for diseases. Antisense technology was the first one to
be developed, and it involves single-stranded RNA molecules that bind to mRNAs to prevent
translation. Although there are many antisense drugs in clinical trials, its success has been
limited, especially with weak Phase III results of Affinitak, a lung cancer antisense drug being
developed by Isis Pharmaceuticals and Eli Lilly. Ribozyme, which is a catalytic RNA molecule
that can recognize and cut specific RNA molecules, is another gene silencing approach. RNA
interference (RNAi) technology is the one that is receiving the most attention from the scientific
community and market. There are several advantages that RNAi offers over others. It is more
specific and efficient in targeting with less side effects and toxicity.
Within RNAi, three subtypes exist. Small interference RNA (siRNA) is double stranded
whereas microRNA (miRNA) is processed from single-stranded RNA and shows partial
complementarity to its targets. Short hairpin RNA (shRNA) contains a high degree of secondary
structure. Although the Irvine nanoparticles can load all these types of RNAi, siRNA delivery
will be focused as miRNA and shRNA research is still in infancy.
IA Since siRNA prevents translation of faulty proteins, its
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Figure 15: Mechanism of siRNA3 9.
by base pairing interactions between the siRNA
antisense strand and the mRNA. Finally, the bound mRNA is cleaved, and sequence-specific
degradation of mRNA results in gene silencing (Figure 1539).
6.2.2 Global siRNA Market
A breakthrough in siRNA research in the recent past led to extreme interest in the field.
Some of the indications include siRNA being named "The Technology of the Year" in 2002 by
Science magazine, "The Next Billion Dollar Breakthrough" in 2003 by Fortune and "The Most
Important Breakthrough in the Past Decade" by MIT. At the end of 2007, PubMed search on
siRNA yielded more than 20,000 entries. In 2006, Professor Andrew Fire from Stanford
University and Professor Craig Mello from University of Massachusetts Medical School won the
Nobel Prize in Medicine for their siRNA research.
The global RNAi revenue is estimated to be $447 million in 2006, and is projected to
grow to $0.9 billion in 2010, with compound annual growth rate (CAGR) of 19%40. Although the
market is relatively small, with the success of RNAi therapy, the technology has the potential to
capture 10% of the pharmaceutical industry, according to Nature Biotechnology. Key end user
groups currently include pharmaceutical and biotechnology companies as well as academic and
government institutions.
The market is largely divided into three sectors by application, with target validation
occupying the biggest share (Figure 1641). The target validation step of the drug discovery
process aims to prove that a given target is directly involved in disease and can be used for
development of a therapeutic drug. Since traditional validation methods are tailored for a
particular gene and require individualized, time-consuming, and often expensive studies, siRNA
is becoming increasingly accepted by the pharmaceutical industry. On the other hand, RNAi
therapeutic market is the smallest one, as there are no commercial products and until recently,
pharmaceutical companies viewed the technology as a risk rather than an opportunity. However,
this sector is rapidly growing with exponential interest from the pharmaceutical industry. The
Irvine nanoparticles will be applicable to all these segments of the market because drug delivery
systems are required in efficient knockdown of mRNA.
In terms of geography, North America possesses a major share of the market with key
RNAi-focused companies, world-class universities and research environment, and readily
available funding for biotechnology and start-up companies (Figure 1741). Europe and Japan are
significant markets, and RNAi market in China and India is rapidly growing.
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The global RNAi market is moderately competitive with 50 companies participating.
Dharmacon, Qiagen, Ambion and Invitrogen control more than 70% of the market. The degree
of competition is expected to increase with entrance of pharmaceutical companies. These
companies are not direct competitors of the Irvine technology. As will be explained later, they
are potential customers.
A summary of market drivers and market restraints for the RNAi technology is displayed
in Table 5. Some of the issues have been already addressed, and others will be discussed further.
The most notable fact is that in vitro and in vivo delivery of siRNA is the most challenging
problem, which is widely agreed across the industry. Since siRNA is too big and negatively
charged to cross the cell membrane, cytosolic delivery is essential. Also, drug delivery systems
are needed to protect siRNA, which is unstable and rapidly cleared in vivo. Therefore, the
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potential for the market is heavily reliant on the efficiency and reliability of delivery tools. The
Irvine technology is addressing the right problem; if successful, it will be able to penetrate the
market.
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Table 5: Market drivers and market restraints for RNAi technology.
6.2.3 U.S. RNAi Delivery Tools Market
Several methods of siRNA delivery exist. Chemical transfection is the most widely used
approach and is dominated by lipid-based systems. Although they are versatile and non-toxic,
they are difficult to design for in vivo use. Electroporation is highly efficient, but is also not
suitable for in vivo use due to cell membrane damage. Plasmid and viral vectors are very
effective. However, potential to induce immune responses has limited their use. CPPs have
established their application in RNAi delivery, but as mentioned previously, research is relatively
new. Finally, nanoparticles are anticipated to grow at the fastest rate (Figure 1842). Some of the
advantages of polymeric nanoparticles include potential of size and charge density tailoring,
stability, extended circulation time, biodegradability and biocompatibility.
U.S. RNAi delivery tools market is moderately competitive with 20 participants.
Invitrogen holds the biggest market share with its leading product, Lipofectamine 2000, which
was the first to penetrate the market. This further indicates that significant improvements have
not been made in this field. As the product is not suitable for in vivo use, the company is focused
on providing products for life science research instead of therapeutics. Nucleofactor, Amaxa's
electroporator, is another significant product (Figure 1942). Based on the past analysis, there is
not much customer loyalty in the market. Fortunate for the Irvine technology, there is ample
room for innovative companies and innovative technologies.
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Figure 18: Breakdown of U.S. RNAi delivery Figure 19: Market share of U.S. RNAi delivery
tools market (2006)42. tools market (2006)42.
6.2.4 Emerging Competitive RNAi Delivery Systems
Novel RNAi delivery systems for clinical and research use are being developed by
several companies. Provita Biotherapeutics, based in Canada, have developed stable nucleic acid
lipid particles (SNALP) that can encapsulate in their aqueous core and deliver siRNA duplexes.
By coating the particles with polyethylene glycol, they remain in the bloodstream over 24 hours.
With maximum silencing above 90%, Provita Biotherapeutics claim that SNALP has 100-fold
better efficiency than other in vivo delivery systems. It was also the first non-viral vector for
siRNA showing activity in non-human primates43.
Mirus Bio Corporation's Dynamic PolyConjugates (DPC) is another potential competitor
to the Irvine nanoparticles, and mimics the natural viral targeting disassembly process for
cytosolic delivery. It includes endosomolytic polymer, charge-masking agents, environmental
responsive linkage chemistry, targeting ligand and siRNA. Its maximum silencing has been
reported to be over 90% as well.44
Calando Pharmaceuticals, cofounded by Professor Mark Davis at California Institute of
Technology, has developed a two-component siRNA delivery system. The first part is composed
of cyclodextrin-containing polycations that bind to the anionic backbone of siRNA. Terminal
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admantane groups prevent aggregation, enhance stability, enable systemic administration and
target tissue of interest. The nanoparticles are 50nm in size and stealthy to the immune system.
They have shown low toxicity in non-human primate studies, and have entered Phase I of clinical
trials45'46. As will be discussed later in the thesis, these companies have successfully leveraged
their technologies to partner with bigger pharmaceutical and biotechnology companies to come
up with therapeutic siRNA products. Because siRNA therapy is expected to be much more
effective than conventional approaches, such as chemotherapy, these technologies will be more
relevant competitors to the Irvine nanoparticles.
6.2.5 Patents Related to siRNA Applications
Patentability of the Irvine nanoparticles has already been established. However, RNAi
technology requires an intellectual property portfolio comprising of patents on RNAi content,
targets, drug delivery systems and methods of complexing RNAi with drug delivery systems.
Since siRNA technology is relatively new, intellectual property landscape used to be somewhat
ambiguous. It is now becoming clearer what the key siRNA patents are.
6.2.5.1 Patents Related to siRNA Content and Targets
This field is the most competitive and still hotly debated over who owns what. Thomas
Tuschl, from Max-Planck Institute, owns two key patents. U.S. Patent No. 7,056,704 broadly
covers methods of making siRNAs for any target with or without chemical modifications
important for siRNA activity. It includes siRNAs with 3'-overhangs at one or both ends of the
double-stranded RNAs and claims siRNA length of 19 to 25 nucleotides that falls within the size
range optimal for RNAi47. U.S. Patent No. 7,078,196 is a development of the previous patent and
claims siRNAs with phosphorothioates, 2'-O-methyl and/or 2'-fluro modifications, which are
important for achievement of drug-like properties for RNAi therapeutics, such as stability and
delivery48. Both patents have been exclusively licensed to Alnylam Pharmaceuticals. Thomas
Tuschl has filed another patent that describes 21 to 23 nucleotide RNAs and their use for
specifically inactivating gene functions49. It is still awaiting decision, and the claims may
become limited. U.S. Patent No. 6,506,559 is one of the earlier siRNA patents, assigned to Nobel
laureates, Andrew Fire and Craig Mello. It describes a method of inhibiting gene expression of a
target gene in many types of cells through dsRNAs comprising of at least 25 nucleotides50 .
Lastly, U.S. Patent No. 5,898,031 and 6,107,094, assigned to Isis Pharmaceuticals, are referred
to as the "Crooke" series. They claim oligomeric compounds that have subsequences of 2-
pentoribofuranosyl nucleosides that activate ribonuclease for target mRNA degradation. They
further include substituent groups for increasing binding affinity of siRNAs to complementary
nucleic acid strands as well as groups for increasing nuclease resistance 51' 52. Both patents have
been licensed to Alnylam Pharmaceuticals (Table 6).
S rtgc R Paen Land s
Patent Inventors
US7,056,704 Tuschl et al.
US7,078,196 Tuschl et al.
US2003/0108923 Tuschl et al.
US5,898,031 Crooke et al.
US6,107,094 Crooke et al.
US6,506,559 Fire et al.
EP1,144,623 Kreutzer et al.
EP1,214,945 Kreutzer et al.
Table 6: Key siRNA patents. Details
Assignee Filing Date Licensure
Max Planck Society 04/27/04 Alnylam (exclusive)
Max Planck Society 04/27/04 Alnylam (exclusive)
Whitehead Institute 09/26/02 Alnylam, CytRx, Merck/Sima
Isis 06/06/96 Alnylam
Isis 06/06/97 Alnylam
Carnegie Institute 12/18/98 Non-exclusive
Ribopharma 01/29/00 Alnylam (exclusive)
Ribopharma 01/29/00 Alnylam (exclusive)
of each patent are described in section 5.2.5.1 and 5.2.5.2.
6.2.5.2 Patents Related to siRNA and Drug Delivery System Complexation
"Kreutzer-Limmer" series, which Alnylam Pharmaceuticals has gained exclusive access
with its acquisition of Ribopharma AG, is also important for siRNA applications. European
Patent No. 1,144,623 describes a method for inhibiting the expression of a given target gene in a
cell of a mammalian in vitro through the use of 15 to 21 nucleotide dsRNAs 53. European Patent
No. 1,214,945 is similar to the previous one, except it claims longer dsRNAs (15 to 49
nucleotides), and is still hotly contested 54. It further covers dsRNAs enclosed by micellar
structures, such as liposomes, and synthetic or natural viral capsids. Polymeric systems are not
covered, and the Irvine nanoparticles will not be infringing upon these methods of complexation
(Table 6). One patent, assigned to Intradigm Corporation, appears problematic for the Irvine
technology. It describes methods to silence target gene expression in vivo by RNAi and claims
composition that comprises a polymeric carrier5 . If approved, numerous preceding patents
would be infringing upon this application. It is unlikely that such broad claims will be accepted
without modifications.
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6.2.5.3 siRNA Patent Strategy
As a drug delivery system-focused company, it will be difficult to invest money and time
to independently develop siRNA molecules and determine their targets. In addition, key patents,
which are mostly owned by Alnylam Pharmaceuticals, present formidable barrier to entry.
Therefore, it will be crucial to obtain licenses to patents on siRNAs and their targets, which will
be further explained in section 6. On the other hand, there are no patents obstructing
complexation of siRNAs with the Irvine nanoparticles. Intellectual property portfolio covering
methods of complexing various RNAi molecules with appropriate nanoparticles should be
developed continuously.
6.2.6 Collaboration with the Pharmaceutical Industry
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Table 7: Partnerships between big pharma/biotech companies and siRNA focused companies 56.
Growing interest in the RNAi technology from the pharmaceutical companies is indicated
by the increase in the number of their platform alliances with the RNAi companies (Table 7). To
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gain access to the promising market, Merck & Co. decided to acquire Sirna Therapeutics for $1.1
billion at 102% premium. In return for nonexclusive access to four therapeutic areas and
acquisition of Alnylam Europe, Roche has paid $273.5 million in cash in addition to $42.5
million equity investment at 41% premium. Alnylam Pharmaceuticals is also eligible for up to
$700 million for development milestones and royalties on product sales56. The deal is considered
to be the largest one of its kind in biotechnology history.
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Table 8: Partnerships between big pharma/biotech companies and siRNA drug delivery system companies 56.
Significant number of collaborations with delivery system companies exists as well since
cytosolic delivery is regarded as the most challenging issue in RNAi. In 2005, Sima Therapeutics,
a subsidiary of Merck & Co., has gained access to Provita Biotherapeutics' SNALP technology.
In exchange, Provita now has access to Sima's siRNA chemistry as well as three targets, and
received $500,000 in cash and $488,000 in equity. Each party will acquire mutual royalties on
products sales involving other party's intellectual property. Pfizer has also made an intent to
~HCQQ~
enter the RNAi market by signing a two-year collaboration involving Mirus Bio Corporation's
delivery methods. Detailed terms are not disclosed, but the deal is expected to be worth
multimillion dollars56 (Table 8).
6.2.7 Summary from siRNA Market Analysis
RNAi market is very attractive for the Irvine technology. First of all, abundant sources of
funding exist, including SBIR funded by the National Institutes of Health (NIH), and $1 billion
Massachusetts biotech initiative. Since cytosolic delivery of siRNA molecules is the most
challenging issue, the Irvine nanoparticles can make a significant impact. Although the market is
relatively competitive with emerging technologies, such as Provita Biotherapeutics' SNALP
technology, there is room for novel drug delivery systems. For instance, Sirna Therapeutics is
especially interested in delivery vehicles with the following characteristics 57:
* Novel polymers and lipids for encapsulation
* Low toxicity and biodegradable
* Amenable to use of process development and manufacturing platforms
* Amenable to molecular targeting strategies
* Long-term storage stability
* Delivery vehicles that improve endosomal escape
* Assemblies of or less than 200nm in diameter
The Irvine nanoparticles meet all of these criteria, assuming that the critical issues are
resolved. Because key patents on siRNA content and targets must be obtained, partnerships are
critical. If strong intellectual property portfolio is established, the Irvine technology has the
potential to earn capital in the form of venture capital, initial public offering (IPO) proceeds,
upfront and milestone payments, royalties on product sales and merger and acquisition activities,
as evidenced by other RNAi companies.
6.3 Subunit and DNA Vaccine Market Analysis
6.3.1 Introduction to Immune System and Vaccines
Protective immunity against pathogens is mediated by the early reactions of innate
immunity and the later responses of adaptive immunity. Adaptive immunity is the primary target
for vaccines. When an antigen, or a component of a foreign substance, is recognized and
internalized by an antigen presenting cells (APC), it is processed and displayed on the surface
through major histocompatibility complexes (MHCs). APCs travel to lymph nodes, where helper
T lymphocytes, or CD4+ TH cells, bind to these complexes through T cell receptors (TCRs), and
secrete cytokines that lead to differentiation and proliferation of B and T lymphocytes. An
additional stimulus, referred to as an adjuvant, is required for this activation step to ensure that
immune responses are induced when they are needed and not against harmless substances. These
effector cells travel to site of infection. Cytotoxic T lymphocytes (CTLs), also known as CD8+
Tc cells, mediate termination of pathogen-infected cells through lysis. B lymphocytes release
antibodies that eliminate extracellular pathogens though various mechanisms. Although effector
cells are short-lived, memory cells confer long-term immunity58. The principle behind
vaccination is to introduce an antigen from a pathogen to develop immunity without causing
infection.
6.3.2 Different Types of Vaccines
Since Edward Jenner's first successful vaccination against smallpox in 1798, many
vaccines of various types have been developed. Vaccines are largely divided into two classes;
prophylactic vaccines endow immunity against future exposure to pathogens whereas therapeutic
vaccines are used to treat ongoing conditions, such as cancer and HIV.
Several types of traditional vaccines exist. First, killed pathogens are previously virulent
microorganisms killed with chemicals or heat, and examples include vaccines against flu, cholera
and hepatitis A virus. On the other hand, live, attenuated pathogens are cultivated under
conditions that disable their virulent properties. Although these vaccines induce strong
immunological response, manufacturing and characterization challenges as well as safety
concerns are significant issues. Subunit vaccines utilize a fragment of an inactivated or
attenuated microorganism. Due to the absence of intact pathogens, adjuvants are required in most
systems. As opposed to the first two types, subunit vaccines are safe and easy to manufacture and
characterize, but immune responses are not as robust.
DNA vaccines, which involve insertion of antigen-encoding viral or bacterial DNA into
human cells, are an emerging technology that has been receiving much attention. Unlike gene
therapy, DNA vaccines do not require lifelong production of antigens. Therefore, change in the
human genome is not a major concern. Some of the advantages include ease of production and
characterization and low cost. However, as demonstrated by clinical trials of DNA vaccines,
efficacy and safety in humans need to be improved 59
6.3.3 Intracellular Delivery to Dendritic Cells
.en Two of the key challenges in vaccine and
immunotherapy technology are to increase the
potential defenses against chronic diseases
that evade the immune system, and to develop
effective immunity after single injections of
vaccine. Recent strategies for developing
preventive and therapeutic vaccines have
Figure 20: Activation of T cells through dendritic cells 61 . focused on the ability to deliver antigens to
dendritic cells (DCs), which are the most effective APCs and crucial in initiating T-cell mediated
immunity60. After antigens are internalized and proteolysed in endosomes, most are loaded onto
MHC class II molecules that activate CD4+ TH cells. Through cross-presentation, for which the
mechanism is still unclear, some are presented on MHC class I molecules that are recognized by
CD8+ Tc cells (Figure206 1). However, this does not lead to strong activation of CTLs. Since
these effector cells play an important role in termination of infected cells and tumor cells,
delivery of antigens to the cytosol, where the intracellular machinery can load them efficiently
onto class I MHC molecules, is required.
6.3.4 Global Vaccine Market
Although vaccine market accounts for only 2% of the global pharmaceutical industry, it
has been growing at an impressive rate led by development of vaccines against cancer, HIV and
hepatitis C virus. The global revenue is estimated to be $10 billion in 2005, and is projected to
grow to $20 billion in 2012, with CAGR of 10.5%62. North America and Europe possess more
than 80% of the market, and the trend is expected to remain stable (Figure 2162). With more than
200 companies participating, the market is highly competitive. GlaxoSmithKline, Sanofi-Pasteur,
Wyeth, Merck & Co. and Chiron control more than 85% of the global market, which is expected
to remain stable, leaving minimal space for other market participants (Figure 2262). These
companies are not direct competitors of the Irvine technology. As will be explained later, they
are potential customers.
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Strengths, Weakness, Opportunities, Threats (SWOT) analysis on the vaccine industry is
displayed in Table 9. Benefits of vaccines are substantial. For instance, its economic value is
unparalleled, with the cost of vaccination being much less than the cost of treatment. Therefore,
vaccine research is heavily supported by the government. Similar to the siRNA market, there are
opportunities for innovative delivery platforms, as efficient delivery presents a major challenge
for many types of vaccines. Whereas intravenous injection is the prominent approach in siRNA,
various routes of administration exist for vaccines, and less invasive and more patient-friendly
methods, such as transdermal and oral delivery, are being developed. For instance, PowerMed
has invented Particle Mediated Epidermal Delivery (PMED) technology, and Iomai
Corporation's liposome carriers, coupled with antigens and adjuvants, target Langerhans cells
underneath the skin63,64
Since killed pathogens and live, attenuated vaccines cannot be applied to cancer, HIV and
hepatitis C virus, subunit and DNA vaccines are being developed. The Irvine technology is
addressing the major challenge in these vaccines, which is cytosolic delivery of antigens and
DNA to increase CTL responses. Even though numerous antigens have been identified that can
generate immunity, the development of subunit and DNA vaccines has had limited success
because of the cytosolic delivery challenge. Discussion on subunit vaccines will be focused in
this thesis since DNA vaccines require an additional mechanism to deliver DNA molecules to the
cell nucleus. The application potential of the Irvine nanoparticles has been confirmed by
measuring the activity of CD8+ Tc cells that have internalized the nanoparticles surface-
complexed with model antigens through interferon-y. Compared to soluble antigens, the core-
shell nanoparticles lowered the required dose by more than 100 fold17. However, further
improvements are needed in addition to the ones discussed in Table 1 and section 4.1. Most
importantly, kinetics of antigen release from the nanoparticles must be tailored so that the
subsequent processing and presentation coincide with the biological timetable of APC-mediated
adaptive immunity in vivo. Immediate antigen release is not optimal in generating an immune
response because premature antigen presentation by APCs is known to induce tolerance65
Adjuvants may also be needed to increase the strength of immune responses. If these issues are
resolved, and the resulting profile is competitive to emerging technologies, the Irvine
nanoparticles will be able to penetrate the market.
SWOT Analysis
Strengths
" Increasing awareness of benefits of vaccines
" Strong pipeline of vaccines
> 15 vaccines in phase III/registration phase
" Support from aid agencies and governments
Opportunities
" Development of more effective combination
vaccines
Increase patient adherence
" Emergence of regional vaccine manufacturers
" Rising costs & limited vaccine budgets for the
major vaccine manufacturers
" Untapped market potential in emerging markets
" Novel delivery platforms & technologies
Weaknesses
" Weak supply security
Shortfall in the manufacturing capacity
" Limited vaccination budgets of emerging
markets
* Absence of structured healthcare systems in
emerging markets
Threats
" Domination by top 5 companies
" Anti-vaccination group
" High-cost of clinical trials
Table 9: SWOT analysis of the vaccine industry.
6.3.5 Emerging Competitive Subunit and DNA Vaccine Delivery Systems
Novel subunit and vaccine delivery systems are being developed in many academic
institutions and companies. The Langer laboratory has synthesized microparticles composed of
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pH-sensitive poly(P-amino esters) and poly(lactic-co-glycolic acid). In extracellular pH, poly(p-
amino esters) are uncharged and water-insoluble. In endolysosomal pH, tertiary amine groups
become protonated, leading to rapid dissolution of the microparticles and release of antigens.
The resulting osmotic pressure gradient and the "proton sponge" effect are responsible for
cytosolic delivery66,67. Professor David Putnam at Cornell University has molecularly engineered
poly(ortho ester) microspheres with optimal kinetics of antigen-encoding DNA release.
Cytosolic delivery is mediated through rapid dissolution of the polymers at acidic pH, but does
not seem to involve the "proton sponge" mechanism 65. Unlike conventional poly(lactic-co-
glycolic acid) microspheres, these systems do not generate acidic environment that would
compromise the bioactivity of antigens. Another advantage is that their size is optimal for
preferential uptake by APCs. When used as vaccines in vivo, these microparticle formulations
induce antigen-specific rejection of transplanted syngenic tumor cells. On the other hand,
Professor Jeffrey Hubbell from EPFL in Switzerland is utilizing ultra-small nanoparticles (25nm)
synthesized from Pluronic-stabilized polypropylene sulfide (PPS) to target lymphatic capillaries
and lymph nodes, rich in DCs. These biodegradable nanoparticles can function as an adjuvants as
well68. Finally, Professor Niren Murthy at Georgia Institute of Technology has developed
microgel particles, 200 to 500nm in diameter, with antigens bound to acid-degradable
crosslinkers. Degradation of the particles leads to osmotic pressure gradient and endolysosomal
escape69 . One disadvantage of this approach is that synthesis is not trivial.
CytRx Corporation's TranzFect technology is one of the most successful delivery
platforms for DNA vaccines on the market. Its microparticulate micelles are formed from
surface-active agents that can associate with DNA molecules and facilitate their delivery into
cells. The micelles themselves act as adjuvants to stimulate an optimized immune response70
Advantages of subunit and DNA vaccines with delivery improvements have already been
discussed. These vaccines will be much more effective against cancer, HIV and hepatitis C virus
compared to conventional therapies, such as chemotherapy and highly active antiviral therapy
(HAART). Therefore, emerging technologies described above will be more relevant competitors
to the Irvine nanoparticles. When comparing different vaccines, several properties must be
addressed. Efficacy in humans is the most important. However, most of the described
technologies, including the Irvine nanoparticles, have not entered clinical trials. Predictive
measurements, such as increase in cytosolic delivery and the activity of antigen-specific CTLs in
vitro or in vivo, can be used. Many systems show slightly less cytosolic delivery than
Lipofectamine 2000. This does not mean that they are worse than Lipofectamine 2000 because
the latter is not suitable for in vivo use. Cytotoxicity is another essential measurement. The
Irvine nanoparticles possess similar non-cytotoxicity compared to the emerging delivery systems,
which should be improved upon incorporation of biodegradability. In vivo stability, ability to
target APCs, routes of administration and cost of synthesis contribute to the fate of a new
vaccine technology. As long as the Irvine nanoparticles display comparable or better overall
profile, they will be able to successfully compete with the emerging technologies.
6.3.6 Patents Related to Vaccine Applications
Similar to the siRNA application, vaccine technology requires an intellectual property
portfolio comprising of patents on antigens, adjuvants, targets, drug delivery systems and
methods of complexing these different components with the nanoparticles.
6.3.6.1 Patents Related to Vaccines and Targets
May important antigens and their targets specific to pathogens have already been
patented. For instance, U.S. Patent No. 5,864,027, assigned to Genentech, describes a method for
preparation of vaccines based on HIV envelope polypeptide gp120. More specifically, it claims a
specific DNA sequence of less than 5kb encoding gp12071. Oncogen owns a patent that covers
protein antigens related to melanoma P97 with specific size and nucleotide sequence. These
antigens can be produced in large quantities via recombinant DNA techniques and/or chemical
synthesis. It further claims these antigens complexed with any kind of pharmaceutical carriers72
Another example is U.S. Patent No. 5,709,995 that claims novel hepatitis C virus-derived
peptides that are recognized by patient CTLs73.
6.3.6.2 Patents Related to Complexing Antigens and Adjuvants with Delivery Systems
There are no issued patents that prevent the Irvine nanoparticles from being complexed
with antigens and/or adjuvants. However, one patent application deserves particular attention.
Patent No. 2006/0189554 describes a vaccine delivery system composed of nanoparticles
complexed with adjuvants and an immunogenic antigen or nucleic acid encoding an
immunogenic antigen. It claims a broad class of nanoparticles and virtually all antigens74
However, it is highly likely that the claims will be more limited since numerous preceding
patents would be infringing upon this application, if approved. In addition, the Irvine
nanoparticles may not require additional adjuvants to invoke strong CTL responses.
6.3.6.3 Vaccine Patent Strategy
Again, it will be difficult to invest money and time to independently develop antigens and
determine their targets as a drug delivery system-focused company. Therefore, it will be
important to collaborate with pharmaceutical and biotechnology companies to obtain licenses to
patents on specific antigens, adjuvants and targets. On the other hand, there are no patents
obstructing complexation of these components with the Irvine nanoparticles. Intellectual
property portfolio covering methods of complexing various antigens and adjuvants with
appropriate nanoparticles should be developed continuously. Based on previous patents, such as
U.S. Patent No. 5,709,879, there is a possibility of claiming a broad class of antigens with
specific drug delivery systems75
6.3.7 Collaboration with the Pharmaceutical Industry
There is a large number of collaborations between small companies and large
pharmaceutical companies in the vaccine industry. For instance, Merck & Co. has received
exclusive rights to Idera Pharmaceuticals' agonist compounds to develop prophylactic vaccines.
In exchange, Idera has acquired $30 million in cash and is eligible for up to $425 million for
development milestones as well as royalties on product sales76. In 2007, Novartis partnered with
Intercell Smart Vaccines to gain access to over 10 vaccine projects, including adjuvant IC31 for
flu vaccines. In return, Intercell received 
€270 million and eligibility of milestone and royalty
payments 7
Significant number of collaborations with drug delivery system companies to develop
subunit and DNA vaccines exists since delivery issue is regarded as the main hurdle. Merck and
Co. acquired the right to use CytRx's TranzFect technology in DNA vaccines targeted to four
infectious diseases, including HIV. CytRx received upfront payment of $2 million and will be
entitled to $4 million for development milestones and royalties on product sales. In addition,
Vical paid $3.75 million in cash to CytRx in order to gain exclusive rights to use TranzFect
technology in areas other than the four diseases mentioned70 . In 2004, MGI Pharma made a $50
million acquisition of Zycos to capture their products including ZYC300, which is a PLGA
microparticle-based vaccine78 (Table 10).
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Table 10: Partnerships between big pharma/biotech companies and vaccine drug delivery system companies.
6.3.8 Summary from Vaccine Market Analysis
Vaccine market, especially for cancer, HIV and hepatitis C virus treatment, is also very
attractive for the Irvine technology. In addition to SBIR, Bill and Melinda Gates Foundation
serves as an abundant source of funding. Since cytosolic delivery of antigens is one of the most
challenging issues for subunit and DNA vaccines, the Irvine technology has the potential to
make a significant impact. Emerging delivery platforms to enhance CTL responses are arising,
but with further improvements, the Irvine nanoparticles will be able to compete with them. Again,
partnerships are required in order to gain access to antigens and their targets. With strong
intellectual property portfolio to cover application of the delivery systems to a broad class of
diseases, and a proper business model, the Irvine technology can generate hefty profit.
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7.0 Business Model
7.1 Supply Chain in the Pharmaceutical Industry
A general diagram of the pharmaceutical supply chain suitable for the Irvine
nanoparticles is depicted in Figure 2379. After identifying an active pharmaceutical ingredient
(API), which is the drug substance, and developing formulations after years of research, a
pharmaceutical company manufactures it into its final packaged form, using its own
manufacturing facilities or contract service manufacturing entities. Starting materials, such as
chemicals and polymers, are usually obtained from reagent companies. Then, retail and
wholesale distributors distribute the product to end-customers, including hospitals and patients.
Figure 23: The pharmaceutical supply chain".
The pharmaceutical supply chain is becoming increasingly disaggregated. Although
contract manufacturing has been largely confined to small pharmaceutical and biotechnology
companies in the past, large organizations intend to outsource most of their drug manufacturing
activities. One of the key drivers is that the big pharmaceutical companies are operating several
of their manufacturing plants at utilization rates of 20 to 30%. This has had a negative impact on
their operating margins. In addition, building or upgrading new facilities, associated costs, and
training personnel to incorporate advances or changes in manufacturing technology have been
increasing at an enormous rate, forcing pharmaceutical companies to outsource such processes
rather than investing in fixed assets. Uncertainty over success of new products, capacity issues,
and short time-to-market are other reasons for this trend. As a result, the global pharmaceutical
contract manufacturing market is expected to grow from $13.4 billion in 2005 to $25.7 billion in
i 
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2011, with CAGR of 11%80. Pharmaceutical companies are also partnering or buying small
biotechnology companies that have the expertise to develop innovative medicines, allowing
themselves to focus on clinical trials, late-stage development and sales and marketing 6 .
7.2 Proposed Business Model for the Irvine Technology
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Figure 24: Proposed business model for the Irvine technology.
A proper business model for an innovative technology is essential in achieving financial
success in the market. Integrating all the information about the technology, potential markets and
supply chain, a business model for the Irvine technology is proposed and shown in Figure 24,
with focus on therapeutic applications. The Irvine technology company (referred to as the
Company) will adopt a hybrid of intellectual property and manufacturing business model. The
Company first needs to partner with large pharmaceutical and biotechnology companies to gain
access to the infrastructure and obtain their APIs, such as protein antigens and siRNA molecules.
After receiving APIs, the Company will develop formulations by modifying the nanoparticles so
that the final products possess optimal drug properties. Then, the Company partners with an
appropriate contract manufacturer that has the expertise and proper facilities to develop the core-
shell nanoparticles. Since emulsion polymerization has existed for a long time in the industry,
this should not be challenging. The pharmaceutical and biotechnology companies will lead the
clinical trials after receiving the Irvine nanoparticles complexed with APIs. The Company will
collaborate during the process to make necessary changes in formulations. Once they are
approved by the Food and Drug Administration (FDA), the contract manufacturer will produce
PI + 
Antigenl
Patien
commercial volume of the final packaged products. The pharmaceutical and biotechnology
companies will market their products, and distributors will distribute them to hospitals, where
patients can finally receive treatments.
The business model is optimal for the Irvine technology as it maximizes return and
minimizes risk, and allows each player to focus on what it does best. The Company will grant
non-exclusive rights to pharmaceutical and biotechnology companies to use the Irvine
nanoparticles for specific applications so that its customers are not limited. In addition to upfront
payments, The Company will be eligible for development milestone payments and royalties on
product sales. The Company will not have to invest in expensive clinical trials, where the drug
molecules have high likelihood of being disapproved. As demonstrated by previous deals, this
type of partnership is common. Contract manufacturing service also reduces risks for all the
reasons stated in the previous section. Even if the Company does possess the capital to establish
its own manufacturing facilities, it will not be wise to do so since there is no guarantee that the
products will be commercialized.
7.3 Value Added across the Supply Chain
One of the most important factors for an innovative technology to succeed in the market
is the ability to add value to all the major players in the supply chain. The pharmaceutical supply
chain has existed for a long time, and if the technology poses any negative effects on one the
major players with strong balance sheets, there will be immense pressure to drive the company
out of business. The Irvine technology has the potential to add significant value across the supply
chain with minimal disruption. The Company must create knowledge of these benefits and
facilitate virtual vertical integration.
Pharmaceutical and biotechnology companies have much to gain from the technology, as
their APIs will be equipped with novel nanoparticles that can solve their delivery issues. Without
proper delivery systems, APIs cannot be commercialized. As will be demonstrated later in the
thesis, profits from product sales will make up for the payments to the Company. Another
significant benefit is increased share price from publicity associated with the profits and success
of addressing unmet medical needs. For siRNA therapy, Alnylam Pharmaceuticals and Sirna
Therapeutics are potential partners since they hold a larger number of key siRNA patents. For
vaccines, GlaxoSmithKline, Merck & Co. and Novartis, which have recently shown strong
earnings, are possible candidates.
The Company will sign non-exclusive or exclusive license agreements for contract
manufacturers to use the patented methods for producing the nanoparticles. Contract
manufacturers will benefit from profit margin, which is the difference between the selling price
and the total cost of production. In addition, they will gain early exposure to innovative products,
allowing them to establish know-how in manufacturing the nanoparticles. Brookwood
Pharmaceuticals and Oakwood Laboratories, which have experience in manufacturing polymeric
drug delivery systems, such as microparticles, are potential candidates 81'82.
Distributors, such as McKesson Corporate and Cardinal Health, are minimally affected
by the Irvine technology, and will generate revenues from the same process as before. In addition
to profits, hospitals can obtain value from the Irvine nanoparticles because they require less time
per patient and are much more effective than standard treatments. Finally, patients who receive
the therapy will value it as a result of its high efficacy and fewer side effects.
7.4 Proposed Timeline
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Figure 25: Possible business timeline for development of the first product.
A possible timeline for development of the first product is displayed in Figure 25. An
initial intellectual property strategy has been discussed in section 4. Assuming that the short-term
critical issues on the research side are resolved in the near future, the Company would be
established with initial investments. After setting up a laboratory with scientists and necessary
equipments, and coming up with a prototype, the Company would seek out to
pharmaceutical/biotechnology companies and contract manufacturers for partnerships. Upfront
and milestone payments can be used for additional investments, such as development of patent
portfolio. The earliest possible date predicted for the first product to come to market is in 2022.
Afterwards, stable cash flow would be generated through royalties on product sales. Initial patent
would expire in 2028, but intellectual property portfolio developed through the timeline can
continue to prevent other companies from using the Irvine technology.
7.5 Risks during and after Commercialization of the Irvine Nanoparticles
Analysis performed in this section and the next two sections is based on an assumption
that the Irvine nanoparticles are successfully commercialized. However, besides critical issues on
the research side covered in section 4.1, risks on the business side are significant as well. First,
there are potential issues with large-scale development of the Irvine nanoparticles. Particles
generated from the manufacturing facilities could display different properties, such as size and
monodispersity. Although the particles have shown to be stable at least one week in neutral
saline, complexation with siRNAs and protein antigens could dramatically lower their stability
and shelf-life4. Additional storage requirements, such as lower temperature and anhydrous
environment, could increase the cost of producing the nanoparticles. Contract manufacturers that
have the expertise in large-scale production of polymeric drug delivery systems have the ability
to solve these problems.
The FDA approval process of a pharmaceutical product can be very challenging. Of five
candidate drugs that make it to human clinical trials, only one is approved for sale83. As seen
with the recently failed Merck's HIV vaccine, promising in vitro and animal study results do not
necessarily translate into successful clinical outcomes 84. Although it varies case by case, about
eight years pass from the time a cancer drug enters clinical trials until it receives approval from
the FDA. Drugs for other diseases have similar timeliness5. Because of this intensive, long-term,
high-risk investment, coupled by the overwhelming odds of failure, report by the Tufts Center
for the Study of Drug Development estimated the average cost to develop a new prescription
drug to be $802 million83. At this point, it is difficult to predict what the cost of clinical trials will
be for the Irvine nanoparticles complexed with APIs. It will be clearer once in vivo data are
obtained. Although the FDA approves the pharmaceutical product as a whole, not individual
components, one should note that the synthetic materials used to produce the core-shell
nanoparticles have not been approved. Compared to drug delivery systems using materials that
are FDA-approved as components of various other drugs and devices, the process could be more
challenging. However, as described in previous sections, the Irvine nanoparticles are likely to
address high-risk groups, such as patients with cancer, and an additional level of toxicity is often
considered acceptable to them if the benefit of the pharmaceutical product is substantial.
Furthermore, regardless of the adverse effects that ensue, the nanoparticle-formulated APIs will
still prove to be safer than traditional treatments, including chemotherapy, surgery and radiation.
This analysis reemphasizes the importance of partnering with pharmaceutical companies that
have the expertise and financial ability to conduct clinical trials.
A long time horizon to commercialize the Irvine nanoparticles, mostly due to the FDA
approval process, increases the likelihood of competing technologies described in previous
sections to be on the market, leaving less market share for late entrants. In addition, it decreases a
period of market exclusivity prior to the expiration of the initial patent. However, the proposed
business model as well as flexibility and broad applicability of the research minimizes the risks
involved in commercializing the core-shell nanoparticles,
8.0 Cost Model
Although the contract manufacturers would be producing the nanoparticles for clinical
trial and commercial purposes, lab-scale production is still needed to develop appropriate
formulations with APIs. A general diagram of the process using two Continuous Stirred Tank
Reactors (CSTRs) is shown in Figure 26. CSTRs provide uniform composition and temperature
of solution in an inert gas environment to maximize yield and purity of the nanoparticles.
Aqueous solution of DEAEMA and PEGDMA is introduced to a CSTR, followed by APS to
initiate emulsion polymerization. After 3 hours of core synthesis, the whole volume is transferred
to another CSTR, where AEMA is introduced to form the shell for 1.5 hours. The process is
continued so that a batch of the nanoparticles can be obtained every 1.5 hours. The desired
products are isolated, unreacted monomers are recovered, and side products are removed.
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Figure 26: General diagram of the lab-scale production of the Irvine nanoparticles.
Assuming that it takes one year to establish proof-of-concept of the technology and
partner with a pharmaceutical company, amount of initial investment required to start and
operate the Company is calculated. Approximately 63% of total costs are made up by the
laboratory equipments, as confocal microscope, transmission electron microscope (TEM) and
scanning electron microscope (SEM) are very expensive8688. Renting a 2,000 square feet
incubator laboratory space in Massachusetts costs about $50,000 per year 89. Labor cost is based
upon hiring two scientists ($100,000 per year) and two research assistants ($50,000 per year),
and the fixed overhead is estimated to be 15% of the total costs. It is assumed that one of the
cofounders will be acting as a Chief Executive Officer in the beginning and will not need to be
paid in salary. Materials used to produce the nanoparticles are very cheap, and therefore, material
cost is insignificant 90' 91 . In total, approximately $1.6 million is required (Figure 27). In addition
to investment by the cofounders, SBIR is a potential source of funding. Phase I and Phase II
_~
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award up to $100,000 and $750,000, respectively 92. The Company can seek funding from other
agencies, such as Massachusetts Biotech Initiative and Bill and Melinda Gates Foundation.
Venture capital investment should be avoided since it is an expensive source of capital, and the
business model does not require large upfront capital requirements.
Fixed Overhead Category Amount In USD
15% Lab Snace
Equipmer% 3
3% Materials $464.50
Labor Cost Lab Space $50,000.00
19% Labor Cost $300,000.0O
Equipment $982,150.00
I•..A. ffL..-k a J "l~ 119r i1
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Total: $1,567,781.76
Figure 27: Breakdown of total costs for the first year of the Company.
9.0 Case Study (Liver Cancer Market)
9.1 Introduction
The market potential of the Irvine nanoparticles has already been established from section
5. To analyze extent of the benefits that the Company and pharmaceutical/biotechnology
companies can extract from the technology through partnerships, it is necessary to concentrate on
a specific disease application, as the type of API used, the competing market and the cost
analysis will vary from one type to another. A case study on the liver cancer market is performed
in this section. Therapeutic area is focused here, but one should note that in addition to being
applicable in a broad range of diseases, the Irvine nanoparticles could be used in research as well
as target validation, which are currently bigger markets as mentioned previously.
Primary liver cancer is one of the most common cancers worldwide with 600,000 patients
diagnosed every year. Secondary liver cancer, which is the metastatic version, has incidence of
500,000 patients38. siRNA therapy holds much promise in this area since genes involved in the
growth and development of liver tumors have been identified recently. Assuming that the Irvine
nanoparticles can be marketed worldwide, the market is expected to be 1,100,000 patients per
year. In the following sections, the core-shell nanoparticles complexed with siRNAs will be
referred to as siRNA therapy.
9.2 Pharmaceutical/Biotechnology Company Perspective
To estimate how much costs are incurred to a pharmaceutical/biotechnology company to
come up with siRNA therapy, several assumptions have been made. First of all, total costs are
calculated from costs of producing siRNAs and conducting the preclinical and clinical trials. The
nanoparticles are obtained from the Company without a fee. Price of siRNA, which is
commercially available at $250 for 0.25mg, is multiplied by 0.75 to discount the profit margin
and to back-calculate the actual cost of producing siRNAs 93. Amount of siRNAs required for
each dose depends on various factors, such as the disease, type of drug delivery system and route
of administration, but Img/kg, which was the siRNA dosage of SNALP-encapsulated siRNAs
introduced to nonhuman primates, is used (dosage information regarding liver cancer treatment
are not yet available)43. Assuming 70kg weight for an average patient, each dose would cost
approximately $52,500. If three doses are needed for complete treatment, based on several
siRNA preclinical data, the cost of producing siRNAs to treat a patient is $157,500 (Figure
28) 43,94
* 1. Cost of sRNA: 250/0.250/0g x 0.75 = S750/mg
S2. Required dosage: 1mg/kg
S3. Cost of sIRNA per dosage: $750/mg x lmgkg x 70kg = $52,500/dose
* 4. Cost of siRNA per patient: S52,500/dose 3 doses = $157,500patient
Figure 28: Calculation of siRNA cost per patient.
As will be seen in the analysis, siRNA content is the most expensive component of
siRNA therapy by far. Without proper drug delivery systems to increase efficacy, each dose may
require more than 10mg/kg, making siRNA therapy untenable94. Another important assumption
is that research and development costs are approximately $800mm, although they can vary case
by case. The number is based on the average cost to develop a new prescription drug83. Lastly,
low demand of 1% is assumed at the outset since it is more expensive than conventional
treatments. In comparison, chemotherapy generally costs the patient between $25,000 and
$65,000 for complete treatment, although it is not uncommon for costs to exceed that range.
Surgery can cost upwards of $10,000. Radiation can range in price from $5,000 to $40,000
depending upon the type and duration of treatment95. If research and development costs are
annualized over 10 years, the total costs of siRNA therapy per patient come out to be about
$164,773 (Figure 29). Since siRNA content is very expensive, larger production volume does not
significantly lower the total costs.
N 1. Liver cancer market: 1,100,000 patientsyear
i 2. Predicted market share: 1% x 1,100,000 patient-syear= 11,000 patients/year
E 3. R&D costs: S8,000,000 (annualized over 10 years)
i 4. Cost of siRNA therapy per patient: ((S157,50Wpatient x 11,000 patients/year) +
($800,000,000/10 years)]/11,000 patientslyear S164773patient
Figure 29: Calculation of siRNA therapy cost per patient.
9.3 Company Perspective
ml. Contract manufacturing
$15mm to set up and operate a manufacturing plant
15 years of lifespan and $0 of scrap value
15% of profit margin
iMateriat cost
S100mg, of nanoparticles/dose x 33,000 doses = 3,300,000mg of nanoparticles
100% efficient scale-up
Total cost: $116,183
Total cost: 1.15 x [($15,000,000/15 years) x 1 year + $116,183)] = $1,287,660
Q2. Formulation
15 years of Ittfespan and $0 of scrap value
3 years of utiltzation for a particula product
Total cost: $1,466,935
i3. Total cost of nanoparticles per patient: [$1,287,660 + ($1,466,935)/10 years]/
11,000 patient/year = $130/patient
Figure 30: Calculation of nanoparticle cost per patient.
Several assumptions have been made to estimate cost of producing the core-shell
nanoparticles, as most of the data involving contract manufacturing service are confidential.
Assuming 100mg of nanoparticles per dose (1:10 (wt/wt) siRNA/nanoparticle 94), and 100%
efficient scale-up from laboratory production, contract manufacture service costs approximately
$1.28 million, which is reasonable based on previous deals. If the Company dedicates three years
into developing a formulation for the core-shell particles complexed with particular APIs, and if
involved costs are annualized over 10 years, the total costs of the nanoparticles per patient is
$130 (Figure 30). This is much lower than the cost of siRNA content. Even though the
nanoparticles make siRNA therapy feasible by significantly lowering the required dosage and
improving various drug properties, they add minimal costs.
Contract manufacturing service occupies bulk of the cost of the nanoparticles at 47%.
Since material cost is minimal, the unit cost of the core-shell particles can fall rapidly with
increase in production volume (Figure 31). In general, if fewer than 30,000 doses are produced, a
substantial amount is added to the final cost of a single dose. Even though the siRNA therapy
will most likely capture a fraction of the 1.1 million liver cancer population initially, production
volume of the nanoparticles is still above 30,000 doses. However, regardless of the production
volume, the cost of the Irvine nanoparticles is significantly less than that of siRNA content.
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Figure 31: Cost breakdown of the Irvine nanoparticles, and cost per dose of the nanoparticles vs. production volume.
9.4 Cost Analysis
Several factors can impact the cost of siRNA therapy. Although the unit cost was
assumed to be constant in section 8.2, economies of scale can significantly lower the cost of
siRNA content. If initial market share turns out to be higher than predicted, larger production
volume will decrease the cost of siRNA therapy. The location of the companies and
manufacturing facilities is another issue. Lower wages in emerging countries, such as China and
India, can reduce the cost as well. However, political and marketing concerns involved with
manufacturing the nanoparticle-formulated siRNAs outside the United States are significant.
This is because stringent Good Manufacturing Practice (GMP) regulations need to be met to
guarantee that the pharmaceutical product is produced in a consistent manner and have the
S..- o
appropriate safety qualifications necessary for its intended use. Next, number of doses per
labeled pack can affect the production costs. Single-dose vials require the same equipment and
labor as multi-dose vials, but yield fewer doses. Therefore, using single-dose packaging as
opposed to multi-dose packaging can increase the production price. Because the overall costs of
siRNA therapy are very high compared to the production price, the increase in cost should be
insignificant. Furthermore, use of single-dose packing offers several advantages for safety
reasons, such as avoiding contamination from needle reuse.
9.5 Pricing siRNA Therapy
As a result of the high costs associated with development of siRNA therapy, higher prices
per dose must be charged to break even. Utility analysis can be performed to determine what the
price needs to be in order to compete with other cancer treatments. Price of $170,000 per patient
is taken as an example, which is above the cost of siRNA therapy for the companies to make
profit. Even though it is much more expensive than standard cancer treatments, improved
treatment efficacy, site-specific administration and reduced adverse side effects that would be
associated with siRNA therapy would make it viable in the market. Because patients' lives are
involved, if siRNA therapy significantly increases survival rate and improves quality of life
compared to other alternatives, higher prices will be accepted. Annual profit for the
pharmaceutical/biotechnology company is $57.5 million. If royalty is assumed to be 5%, the
Company would receive $2.9 million every year in addition to upfront payments and
development milestone payments. The case study only concerns the liver caner market. There is
no question how profitable the Irvine technology and the business model can be, if the
nanoparticles are successfully commercialized.
10.0 Conclusion
The technical and economic evaluation of a novel drug delivery system has been
performed throughout this paper. Developed in the Irvine laboratory, the pH-responsive core-
shell nanoparticles utilize the "proton sponge" effect to mediate cytosolic delivery of membrane-
impermeable molecules. Compared to other intracellular drug delivery systems, these
nanoparticles offer several advantages, including efficient cytosolic delivery and low
cytotoxicity. Another advantage is that emulsion polymerization, which is the process used to
synthesize the Irvine nanoparticles, allows composition of the shell to be separately tuned to
facilitate drug binding and particle targeting. Variation of the shell structure did not compromise
the endolysosomal-escaping capability of the pH-responsive core. These experimental results
demonstrate flexibility and broad applicability of the nanoparticles, as they can bind to and
deliver various types of drug agents with modification of the shell. However, critical issues on
the research side remain and indicate that the technology is still in early stage development.
From detailed patent and literature search, the Irvine nanoparticles should be patentable, and a
preliminary patent strategy has been outlined.
Since many potentially powerful therapeutic strategies for the treatment of disease
depend on cytosolic delivery, numerous applications of the nanoparticles exist. Applications to
siRNA delivery and vaccines have been examined in depth. Cytosolic delivery is one of the main
challenges in these examples. Therefore, multimillion dollar deals between pharmaceutical
companies and drug delivery system-focused companies have already been established. Because
key patents on siRNA/antigen must be obtained, partnerships with large pharmaceutical and
biotechnology companies are crucial. If overall profile of the core-shell nanoparticles is
comparable to that of emerging drug delivery systems, and a strong intellectual property
portfolio is developed, the Irvine technology should be able to compete in the market.
A hybrid of intellectual property and manufacturing business model that maximizes
return and reduces risk has been proposed in this thesis. It allows each player to focus on what it
does best; the Irvine technology company will develop formulations, contract manufacturers will
produce the nanoparticles, and pharmaceutical companies will concentrate on clinical trials, late-
stage development and sales and marketing. The model also adds value across the existing
supply chain. However, risks on the business side, including the FDA approval process, are
significant as well. As with any pharmaceutical products, there is no guarantee that the
nanoparticles will be commercialized. Finally, a case study on the liver cancer market is
performed to analyze the extent of benefits that the Irvine nanoparticle company and
pharmaceutical companies can extract from the technology through partnerships. Even though
the core-shell particles themselves are inexpensive, siRNA content can make the therapy very
costly. Because patients' lives are involved, if siRNA therapy significantly increases survival
rate and improves quality of life compared to other alternatives, higher prices will be accepted. A
simplistic cost analysis has shown that commercial development of the Irvine nanoparticles can
be a successful endeavor.
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